Sosei Heptares (the corporate brand of Sosei Group Corporation) is a research-focused biotechnology group, publicly listed in Japan (TSE: 4565) and with sites in Tokyo, London and Cambridge (UK).

Our mission is to make a significant contribution to improving the quality of life and health of people around the world. To achieve this, we will discover, design and develop the most innovative and effective medicines for patients worldwide, through our world-leading patent-protected StaR® technology and platform.

Our primary focus is the discovery and early development of new medicines originating from our proprietary G Protein-Coupled Receptor (GPCR)-targeted StaR® technology and Structure-Based Drug Design (SBDD) platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including CNS, immuno-oncology, gastroenterology, inflammation and other rare/specialty indications.

We have established partnerships with some of the world’s leading pharmaceutical companies, including Abbvie, AstraZeneca, Genentech (Roche), Novartis, Pfizer and Takeda; and additionally, with multiple emerging biotechnology companies.

Sosei Heptares has approximately 148 employees based at its new R&D research facility at Granta Park. The size of the company ensures a transparent linkage between all activities from early discovery through to clinical development.

We are currently looking to strengthen our Molecular Pharmacology team and are now seeking to recruit a highly motivated laboratory-based in vitro pharmacologist to join our team at Scientist or Research Scientist level (depending on experience). The Molecular Pharmacology team is responsible for both new drug target validation and supporting all drug discovery phases up to pre-clinical candidate (PCC) selection via performing assays to study pathological characteristics of GPCRs in disease.

This role will include tasks relating to assay development, provision of routine small/large molecule screening and more detailed mechanism of action studies in native cellular systems.

The successful candidate is expected to have:

• An undergraduate degree or PhD in pharmacology or similar biological sciences or relevant industrial experience.
• Practical laboratory experience (such as mammalian cell culture, experience in recombinant cell-based assays).
• Strong numerical and analytical ability.
• Excellent communication and interpersonal skills and demonstrated capability to operate in a collaborative and entrepreneurial environment.
• The ability to communicate clearly, both verbally and in written reports, in English.

Desirable but not essential includes:

• Prior experience in GPCRs
• Previous experience using automation (such as automatic liquid handlers).

Applicants must be able to demonstrate the right to work in the UK.

We offer a competitive salary, commensurate with qualifications and experience, and benefits package including pension and healthcare schemes.

The successful candidate will be employed by Heptares Therapeutics Ltd, a UK wholly owned subsidiary of Sosei Group Corporation. 

Sosei Heptares is an equal opportunities employer.

Applications should include a covering letter, providing a short description of the background to their interest in the role, with curriculum vitae including the names and contact details for two referees. Please apply through our on-line jobs portal with your application in pdf format, quoting reference number 2020-3MP.

The closing date for applications is 18th October 2020.

Strictly no agencies.